Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Comparison Study Of Lucentis, Avastin And Eylea In DME Starts With NIH Funding

This article was originally published in The Pink Sheet Daily

Executive Summary

The study’s sponsor, the NIH-funded Diabetic Retinopathy Clinical Research Network, highlighted the cost disparity between treatments for diabetic macular edema in a summary of the study’s purpose.

You may also be interested in...



Eylea, Avastin Both Get A Boost From NIH Comparative Study In DME

The first head-to-head comparison of Eylea, Avastin and Lucentis in diabetic macular edema shows a superior benefit for Eylea in patients with more advanced vision loss and that Avastin is as effective as the other two drugs in other patients.

Market Snapshot: Diabetic Macular Edema, Another Blockbuster Opportunity For Retinal Drugs?

Having relatively rapidly built a multi-billion dollar market in wet age-related macular degeneration, biotech and pharma companies may be about to repeat the exercise with diabetic macular edema, a complication of diabetes that’s growing in importance as the population ages and the disease spreads.

Genentech Says Lucentis DME Product Will Ship Shortly

FDA approves lower, monthly 0.3 mg dose of injectable Lucentis for diabetic macular edema, the regimen Genentech had suggested was most appropriate. Questions remain about the commercial picture, considering competition from the similar but much cheaper Avastin.

Related Content

Topics

UsernamePublicRestriction

Register

PS074506

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel